Beyond Air Reports Flat Revenue but Eyes FDA Approval for Next-Gen LungFit PH — Beyond Air, Inc.

Event summary

Beyond Air reported $1.8 million in revenue for Q2 2026, unchanged from the prior year.
The company reaffirmed its revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027.
A PMA supplement for the second-generation LungFit PH system is under FDA review, with approval expected in 2H 2026.
Beyond Air secured up to $30.1 million in financing to support international expansion and U.S. commercial launch of its next-gen product.

The big picture

Beyond Air is positioning itself for a potential inflection point in revenue growth, leveraging pending FDA approval for its next-generation LungFit PH system. The company's strategic focus on expanding market access through GPO agreements and international distribution networks aligns with broader industry trends toward decentralized nitric oxide therapy solutions. With $15.2 million in cash reserves as of Q2 2026, Beyond Air aims to capitalize on a significantly larger addressable market pending regulatory approval.

What we're watching

Regulatory Approval: The timing and outcome of the FDA review for the second-generation LungFit PH system will determine Beyond Air's commercial launch trajectory.
Revenue Growth: Whether Beyond Air can sustain its projected 110% year-over-year revenue growth in 2027 hinges on successful market adoption of the next-gen product.
Financial Health: The pace at which Beyond Air deploys its recent $30.1 million financing will impact its ability to expand globally and maintain compliance with Nasdaq listing requirements.